statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	5.933
EU - Europa	5.085
AS - Asia	2.610
SA - Sud America	257
AF - Africa	30
OC - Oceania	11
Continente sconosciuto - Info sul continente non disponibili	5
Totale	13.931

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.760
IT - Italia	2.508
UA - Ucraina	957
SG - Singapore	941
CN - Cina	433
TR - Turchia	384
VN - Vietnam	382
SE - Svezia	375
HK - Hong Kong	340
DE - Germania	273
FI - Finlandia	268
BR - Brasile	226
IE - Irlanda	205
GB - Regno Unito	151
RU - Federazione Russa	129
CA - Canada	127
FR - Francia	119
IN - India	51
MX - Messico	39
PL - Polonia	22
JP - Giappone	21
ZA - Sudafrica	17
ES - Italia	15
BD - Bangladesh	14
AR - Argentina	13
NL - Olanda	13
BE - Belgio	12
IQ - Iraq	10
NZ - Nuova Zelanda	9
AT - Austria	8
CH - Svizzera	8
CZ - Repubblica Ceca	7
LT - Lituania	7
CO - Colombia	6
PK - Pakistan	6
UZ - Uzbekistan	6
EG - Egitto	5
EU - Europa	5
SA - Arabia Saudita	5
AE - Emirati Arabi Uniti	4
PY - Paraguay	4
RS - Serbia	4
KE - Kenya	3
KR - Corea	3
LB - Libano	3
AU - Australia	2
DZ - Algeria	2
EC - Ecuador	2
GR - Grecia	2
MA - Marocco	2
PE - Perù	2
TT - Trinidad e Tobago	2
AZ - Azerbaigian	1
BB - Barbados	1
BH - Bahrain	1
BY - Bielorussia	1
CL - Cile	1
CR - Costa Rica	1
DK - Danimarca	1
GL - Groenlandia	1
GY - Guiana	1
HN - Honduras	1
ID - Indonesia	1
JM - Giamaica	1
MO - Macao, regione amministrativa speciale della Cina	1
PH - Filippine	1
PS - Palestinian Territory	1
TN - Tunisia	1
TW - Taiwan	1
UY - Uruguay	1
VE - Venezuela	1
Totale	13.931

Salva come PNG Salva come JPEG

Città	#
Milan	1.837
Jacksonville	724
Chandler	529
Singapore	526
Fairfield	453
Ashburn	424
Woodbridge	354
Hong Kong	339
Wilmington	259
Princeton	245
Ann Arbor	229
Izmir	229
Nyköping	216
Dallas	215
Beijing	210
Dublin	205
Dearborn	194
Seattle	194
Houston	178
Dong Ket	155
Boardman	147
Cambridge	134
Rome	126
Como	103
Toronto	99
San Mateo	92
New York	89
The Dalles	88
Los Angeles	68
San Diego	55
Chicago	48
Ogden	38
Munich	34
Düsseldorf	29
São Paulo	27
Santa Clara	26
London	25
Mexico City	23
Verona	23
Pune	22
Hefei	20
Warsaw	20
Guangzhou	19
Tokyo	19
Helsinki	18
Ho Chi Minh City	17
Chennai	16
Turku	16
Manchester	15
Nanjing	15
Council Bluffs	13
Orem	13
Brooklyn	12
Brussels	12
Johannesburg	11
Kunming	11
Hanoi	10
Boston	9
Frankfurt am Main	9
Montreal	9
Norwalk	9
St Petersburg	9
Stockholm	9
Denver	8
Jinan	8
Phoenix	8
Redwood City	8
Atlanta	7
Christchurch	7
Fuzhou	7
Ponte Lambro	7
Poplar	7
Raleigh	7
San Francisco	7
Washington	7
Auburn Hills	6
Curitiba	6
Rozzano	6
Shanghai	6
Villanova D'asti	6
Zhengzhou	6
Amsterdam	5
Changsha	5
Charlotte	5
Falls Church	5
Goiânia	5
Querétaro	5
Vanzaghello	5
Belgrade	4
Cape Town	4
Casorezzo	4
Columbus	4
Hebei	4
Hounslow	4
Nuremberg	4
Ottawa	4
Seveso	4
Shenyang	4
Tashkent	4
Varese	4
Totale	9.529

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	206
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	202
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	193
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	185
The MHC class II transactivator: prey and hunter in infectious diseases	182
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	180
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	180
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	172
New strategies of mammary cancer vaccination	170
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	167
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	162
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	160
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	156
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	151
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	150
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	149
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	148
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	145
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	143
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	142
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	140
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	139
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	139
Analysis of microchimerism in thyroid autoimmune diseases	138
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	135
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	130
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	130
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	129
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	129
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	129
The complex liaison between cachexia and tumor burden	129
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	127
MHC immunoevasins: protecting the pathogen reservoir in infection	126
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	125
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	124
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	122
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	122
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	122
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay	121
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	120
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	120
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	119
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	119
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	119
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	118
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	117
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	117
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	116
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	116
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	114
Regulation of HLA antigen expression in HIV infected cells	114
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	113
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	113
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	112
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	112
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	112
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	111
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	108
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	108
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	106
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	106
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	105
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	105
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	105
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	105
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	104
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	104
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	103
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	103
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	101
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	101
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	101
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	101
The complex liaison between vulnerability to cachexia and tumor burden.	101
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	100
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	100
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	99
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	98
Imaging guided percutaneous microwave ablation of tumors.	98
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	97
Regulation of HLA antigen expression in phagocytes with mycobacteria	96
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	96
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	95
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	95
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	94
Inhibition of HTLV-2 viral replication by the MHC class II transcriptional activator (CIITA)	94
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	93
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA	92
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	92
HLA-DQ expression is differently regulated from -DR and -DP	92
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	91
Metabolic Rewiring in the Tumor Microenvironment to Support Immunotherapy: A Focus on Neutrophils, Polymorphonuclear Myeloid-Derived Suppressor Cells and Natural Killer Cells	91
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ	90
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat	89
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	89
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	88
Temporal and quantitative relations between CIITA and HLA class II expression	88
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	87
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan.	87
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	87
Totale	12.066

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	56.526
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	56.526

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1.099	0	0	0	0	0	161	44	143	264	59	138	290
2021/2022	1.101	141	133	106	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.818	452	438	505	488	499	220	24	25	104	17	2	44
2024/2025	1.712	13	47	320	32	84	70	79	86	221	109	133	518
2025/2026	1.759	307	235	118	553	429	117	0	0	0	0	0	0
Totale													13.982